1. Home
  2. ADCT vs PLBY Comparison

ADCT vs PLBY Comparison

Compare ADCT & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.13

Market Cap

136.1M

Sector

Health Care

ML Signal

HOLD

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.19

Market Cap

128.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADCT
PLBY
Founded
2011
1953
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Recreational Games/Products/Toys
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
136.1M
128.3M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
ADCT
PLBY
Price
$1.13
$1.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$7.75
$3.00
AVG Volume (30 Days)
796.4K
669.2K
Earning Date
05-04-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
30.86
87.50
EPS
N/A
N/A
Revenue
$81,357,000.00
$120,928,000.00
Revenue This Year
N/A
$9.17
Revenue Next Year
$66.49
$7.10
P/E Ratio
N/A
N/A
Revenue Growth
14.85
4.13
52 Week Low
$0.78
$1.08
52 Week High
$4.98
$2.75

Technical Indicators

Market Signals
Indicator
ADCT
PLBY
Relative Strength Index (RSI) 40.67 46.72
Support Level $1.03 $1.09
Resistance Level $1.17 $1.30
Average True Range (ATR) 0.07 0.06
MACD 0.02 0.01
Stochastic Oscillator 41.18 42.50

Price Performance

Historical Comparison
ADCT
PLBY

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

Share on Social Networks: